Sanara MedTech (NASDAQ:SMTI) Shares Down 0.2%

Sanara MedTech Inc. (NASDAQ:SMTI)’s stock price was down 0.2% on Wednesday . The company traded as low as $31.53 and last traded at $31.60. Approximately 9,594 shares traded hands during trading, a decline of 28% from the average daily volume of 13,296 shares. The stock had previously closed at $31.65.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reduced their price objective on shares of Sanara MedTech from $49.00 to $44.00 and set an “overweight” rating for the company in a research report on Wednesday, March 27th.

Sanara MedTech Price Performance

The firm has a market cap of $272.39 million, a PE ratio of -60.77 and a beta of 1.57. The stock’s fifty day moving average price is $36.55 and its 200-day moving average price is $34.73. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04.

Sanara MedTech (NASDAQ:SMTI) last released its earnings results on Monday, March 25th. The company reported ($0.03) earnings per share (EPS) for the quarter. Sanara MedTech had a negative return on equity of 11.12% and a negative net margin of 6.62%. The business had revenue of $17.69 million for the quarter. As a group, equities analysts expect that Sanara MedTech Inc. will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanara MedTech

A number of large investors have recently modified their holdings of SMTI. Tower Research Capital LLC TRC grew its holdings in shares of Sanara MedTech by 363.4% during the third quarter. Tower Research Capital LLC TRC now owns 797 shares of the company’s stock worth $25,000 after buying an additional 625 shares in the last quarter. UBS Group AG grew its holdings in shares of Sanara MedTech by 138.8% during the first quarter. UBS Group AG now owns 609 shares of the company’s stock worth $25,000 after buying an additional 354 shares in the last quarter. Barclays PLC purchased a new stake in shares of Sanara MedTech in the second quarter valued at about $30,000. Gladius Capital Management LP purchased a new stake in shares of Sanara MedTech in the fourth quarter valued at about $45,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Sanara MedTech in the second quarter valued at about $51,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.